These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27212962)

  • 1. A comparison of drug therapy problems in patients eligible and ineligible for provincial medication review programs in Canada.
    Pammett R; Jorgenson D
    Can Pharm J (Ott); 2016 May; 149(3):125-9. PubMed ID: 27212962
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating glioma therapies: modeling treatments and predicting outcomes.
    Kirby S; Brothers M; Irish W; Florell R; Macdonald D; Schold C; Cairncross G
    J Natl Cancer Inst; 1995 Dec; 87(24):1884-8. PubMed ID: 7494233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.
    Wang J; Qiao Y; Shih YC; Jamison JJ; Spivey CA; Li L; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
    Am Health Drug Benefits; 2014 Sep; 7(6):346-58. PubMed ID: 25558303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing of alcohol in Canada: A comparison of provincial policies and harm-reduction opportunities.
    Giesbrecht N; Wettlaufer A; Thomas G; Stockwell T; Thompson K; April N; Asbridge M; Cukier S; Mann R; McAllister J; Murie A; Pauley C; Plamondon L; Vallance K
    Drug Alcohol Rev; 2016 May; 35(3):289-97. PubMed ID: 26530717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
    Curran WJ; Scott CB; Weinstein AS; Martin LA; Nelson JS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG
    J Clin Oncol; 1993 May; 11(5):857-62. PubMed ID: 8487050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks.
    Hyshka E; Anderson-Baron J; Karekezi K; Belle-Isle L; Elliott R; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Hathaway A; Wild TC
    Harm Reduct J; 2017 Jul; 14(1):50. PubMed ID: 28747183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The financial burden of out of pocket prescription drug expenses in Canada.
    Caldbick S; Wu X; Lynch T; Al-Khatib N; Andkhoie M; Farag M
    Int J Health Econ Manag; 2015 Sep; 15(3):329-338. PubMed ID: 27878679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy choices for pharmacare; the need to examine benefit design, medication management strategies and evaluation.
    Sketris IS; Brown MG; Murphy AL
    Healthc Pap; 2004; 4(3):36-45; discussion 68-72. PubMed ID: 15114068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Medicare modernization act on low-income persons.
    Havrda DE; Omundsen BA; Bender W; Kirkpatrick MA
    Ann Intern Med; 2005 Oct; 143(8):600-8. PubMed ID: 16230727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with providing drugs for seniors in Canada.
    Gray J
    Am J Geriatr Cardiol; 2005; 14(6):313-6. PubMed ID: 16276129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The provincial role in the Canadian welfare state: the influence of provincial social policy initiatives on the design of the Canada Assistance Plan.
    Bella L
    Can Public Adm; 1979; 22(3):439-52. PubMed ID: 10247097
    [No Abstract]   [Full Text] [Related]  

  • 20. Modifications to the National Dental Examining Board of Canada's certification process.
    Gerrow JD; Boyd MA; Donaldson D; Watson PA; Henderson B
    J Can Dent Assoc; 1998 Feb; 64(2):98-100, 102-3. PubMed ID: 9509815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.